Introduction
• Pancreatic Neuroendocrine tumours, P-NETs, comprise 2-3% of all pancreatic tumours 1 .
• Usually classifi ed as functional or non-functional based on whether these secrete biologically active amines, causing specifi c syndromes or not. Even non-functional P-NETs in majority of cases secrete substances, not associated with any specifi c syndrome, like Chromogranin A and Chromogranin B and Pancreatic Polypeptide (PP) 2 .
• An estimated 2% of all the neuroendocrine tumours secrete Pancreatic Polypeptide exclusively and are sometimes called PPomas
3
. This is a rare group of NETs and in almost all the reported cases, the source, usually a tumour, was originating from the pancreas.
Case History
• The case we describe is unique as the source of excess PP is neither coming from the pancreas nor the intestine.
• This 65-year old gentleman with background of type 2 DM presented with a few weeks' history of explosive diarrhoea with no fl ushing, pruritus or other symptoms usually associated with carcinoid syndrome.
• CT scan showed a soft tissue mass with calcifi cations close to the mesentery at the level of the lower poles of the kidneys.
• A full biochemical profi le for work up of neuroendocrine tumour was carried out which showed raised Chromogranin A and B and PP levels with rest of profi le unremarkable including Gastrin, Glucagon, Somatostatin, VIP and 24hour urine 5HIAA.
• The mass was confi rmed as somatostatin avid lesion with no uptake elsewhere on the Octreotide scan.
• Patient was referred to the neuroendocrine oncologist for further management who commenced Sandostatin LAR. 
Conclusion and recommendation
• A thorough literature search has not shown previously reported extra-pancreatic PPoma causing diarrhoea and no other symptoms.
• Usually PPomas are considered silent but we believe this is no longer true and can arise from outside pancreas.
• Further research however, is warranted into their origin which we now believe can even be extra-pancreatic and extra-intestinal.
Octreotide Scan: Somatostatin Avid lesion with no uptake elsewhere
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